STAAR Surgical Company (STAA) Cash Flow Statement

The wide dispersion in the OCF/NI ratio suggests that reported net income is not a reliable predictor of cash generation, likely due to large swings in working capital and non-cash items like stock-based compensation. For instance, in Q1 2026, a $5.2M net loss was accompanied by a $21.7M operating cash outflow, a -4.17 ratio, highlighting how accruals and working capital can dramatically distort the cash reality. This volatility warrants caution when using net income as a proxy for underlying business performance.

The FCF margin rebounded to 20.5% in Q2 2026, a stark improvement from the -23.7% in the prior quarter. However, this positive result appears driven by a sharp reversal in working capital, which contributed $2.7M to cash flow after a massive $42.7M drain in Q1. The underlying operating cash flow of $19.7M is encouraging, but the extreme quarterly volatility indicates that the business has not yet achieved consistent, self-funding free cash flow generation.

The massive $42.7M working capital outflow in Q1 2026, followed by a modest $2.7M inflow in Q2, suggests significant lumpiness in collections or inventory management, possibly related to the consignment model and distributor relationships in China. This pattern indicates that the company's cash flow is highly sensitive to the timing of receivables and inventory movements, which can obscure the true operational trend. Investors should monitor whether these large swings normalize or continue to create unpredictable cash flow.